Reuters logo
BRIEF-Immune Therapeutics says NAFDAC approves Lodonal
2016年4月27日 / 下午3点17分 / 1 年前

BRIEF-Immune Therapeutics says NAFDAC approves Lodonal

April 27 (Reuters) - Immune Therapeutics Inc

* NAFDAC approved lodonal as over counter, non-toxic adjunct therapy in treatment of HIV/Aids and immune system regulator Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780; )

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below